1. Home
  2. GRF vs XLO Comparison

GRF vs XLO Comparison

Compare GRF & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eagle Capital Growth Fund Inc.

GRF

Eagle Capital Growth Fund Inc.

HOLD

Current Price

$10.82

Market Cap

43.9M

Sector

Finance

ML Signal

HOLD

XLO

Xilio Therapeutics Inc.

HOLD

Current Price

$0.57

Market Cap

41.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GRF
XLO
Founded
1989
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
43.9M
41.8M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
GRF
XLO
Price
$10.82
$0.57
Analyst Decision
Buy
Analyst Count
0
1
Target Price
N/A
$2.00
AVG Volume (30 Days)
3.0K
572.5K
Earning Date
01-01-0001
03-10-2026
Dividend Yield
3.70%
N/A
EPS Growth
N/A
N/A
EPS
1.16
N/A
Revenue
N/A
$31,804,000.00
Revenue This Year
N/A
$626.78
Revenue Next Year
N/A
$79.08
P/E Ratio
$8.15
N/A
Revenue Growth
N/A
588.40
52 Week Low
$7.93
$0.50
52 Week High
$10.19
$1.70

Technical Indicators

Market Signals
Indicator
GRF
XLO
Relative Strength Index (RSI) 48.65 45.49
Support Level $10.75 $0.50
Resistance Level $11.09 $0.61
Average True Range (ATR) 0.16 0.04
MACD -0.00 0.00
Stochastic Oscillator 45.60 55.80

Price Performance

Historical Comparison
GRF
XLO

About GRF Eagle Capital Growth Fund Inc.

Eagle Capital Growth Fund Inc is a diversified closed-end investment company. The fund's objective is long-term growth utilizing the concept of total return for selecting investments. It seeks to achieve its investment objectives by investing predominantly in U.S. issuer common stock by giving preference to high-quality companies, where high quality denotes substantial operating income margins, high returns on capital, and robust balance sheets.

About XLO Xilio Therapeutics Inc.

Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies and immune cell engagers.

Share on Social Networks: